Please use this identifier to cite or link to this item:
https://islhd.intersearch.com.au/islhdjspui/handle/1/6720| Title: | Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma |
| ISLHD Author: | Parmar, Gurdeep |
| Authors: | Parmar G;Capra M;Hungria V;Seguro FS;Dimopoulos MA;Delimpasi S;Špička I;Minařík J;Marques H;Pour L;Mihályová J;Yuda J;Sunami K;Esteves G;Chmielewski C;Soufflet C;Yu D;Comerford E;Suzan F;Cordero P;Zhang R;Quach H |
| Keywords: | Patient Reported Outcomes;Myeloma |
| Date Published: | 1-Oct-2026 |
| Citation: | Clin Lymphoma Myeloma Leuk. 2026 Sep 3:S2152-2650(26)03286-6. doi: 10.1016/j.clml.2026.08.019. |
| URI: | https://islhd.intersearch.com.au/islhdjspui/handle/1/6720 |
| DOI: | 10.1016/j.clml.2026.08.019 |
| Journal Title: | Clin Lymphoma Myeloma Leuk |
| Appears in Collections: | Research publications from current and former ISLHD staff. |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.